IONS Investor Alert: Levi & Korsinsky Notifies Investors of an Investigation Into Ionis Pharmaceuticals (IONS)

Ionis Pharmaceuticals (NASDAQ: IONS) shareholders saw their holdings slide after the Phase-3 CARDIO-TTRansform trial missed its primary endpoint -- and now have legal rights worth protecting. Levi & Korsinsky is investigating.

NEW YORK--(BUSINESS WIRE)--Shares of Ionis Pharmaceuticals fell more than 20% in the early trading on July 9, 2026, after the Company announced that its late-stage Phase-3 CARDIO-TTRansform trial, partnered with AstraZeneca, failed to meet its primary endpoint. If you purchased IONS securities and suffered a loss, you are encouraged to protect your shareholder rights now. You may also contact Joseph E. Levi, Esq. via email at [e-mail] or by telephone at [phone].

The CARDIO-TTRansform trial was designed to test whether the Company's therapy could reduce combined cardiovascular death and recurrent events in patients with transthyretin-mediated amyloid cardiomyopathy. On July 9, 2026, the Company disclosed the trial did not meet that primary endpoint. The share price abruptly declined after the news was released.

Levi & Korsinsky is investigating potential securities law violations on behalf of IONS investors. The investigation focuses on whether the Company adequately disclosed the risks tied to the CARDIO-TTRansform program prior to the July 9, 2026 readout. Shareholders retain important legal rights, and those rights are best preserved by acting promptly.

Investors who purchased Ionis Pharmaceuticals shares and lost money are encouraged to submit your IONS losses for review. You may also contact Joseph E. Levi, Esq. via email at [e-mail] or by telephone at [phone].

Levi & Korsinsky, LLP | Top 50 Securities Firm | [phone] | www.zlk.com

Frequently Asked Questions About the IONS Investigation

Q: Who is eligible to participate in the IONS investigation? A: Investors who purchased IONS stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.

Q: How much did IONS stock drop? A: Shares fell over 20% after the Company disclosed that its Phase-3 CARDIO-TTRansform trial failed to meet its primary endpoint. Investors who purchased shares and suffered losses may be eligible to seek recovery.

Q: What if I already sold my IONS shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought IONS and sold at a loss may still participate in the investigation.

Q: What if my IONS losses are small -- is it still worth contacting a lawyer? A: Yes. There is no minimum loss amount required to participate in the investigation.

Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.

Q: What does it cost me to participate? A: There is no upfront cost to participate. Securities investigations and any resulting actions are generally handled on a contingency basis. No upfront fees, no retainer, and no out-of-pocket costs.

Q: What if I live outside the United States? A: U.S. securities fraud investigations generally cover purchases on U.S. exchanges regardless of the investor's country of residence.

Q: What do IONS investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at [e-mail] or [phone]. No immediate action is required to remain eligible to participate in the investigation.

Attorney Advertising. Prior results do not guarantee similar outcomes.